G. Barosi

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) (2006)

Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., ...

Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and...

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A (2001)

Marchetti, M., Quaglini, S., Barosi, G.

Carriers of a double thrombophilic mutation (factor V Leiden and prothrombin G20210A) are at high risk of a recurrent venous thromboembolism (VTE), and may benefit from a longer...

Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. (1996)

Cazzola, M, Ponchio, L, De Benedetti, F, Ravelli, A, Rosti, V, Beguin, Yves, ...

Systemic-onset juvenile chronic arthritis (SoJCA) is associated with high levels of circulating interleukin-6 (IL-6) and is frequently complicated by severe microcytic anemia whose pathogenesis is...

Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. (1992)

Cazzola, M, Ponchio, L, Beguin, Yves, Rosti, V, Bergamaschi, G, Liberato, N L, ...

We have used recombinant human erythropoietin (rHuEPO) in a phase I/II clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered...

Analysis of serum ferritin changes during erythropoietin therapy in haemodialysis patients (1992)

Piazza, V., Poggio, F., Merlo, C., Palestra, P., Barosi, G., Salvadeo, A.

Analysis of serum ferritin changes during erythropoietin therapy in haemodialysis patients (1992)

Piazza, V, Poggio, F, Merlo, C, Palestra, P, Barosi, G, Salvadeo, A

Erythropoietin as treatment of haemodialysis-related porphyria cutanea tarda (1992)

Piazza, V., Villa, G., Galli, F., Segagni, S., Bovio, G., Poggio, F., ...

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.

Barosi, G., Marchetti, M., Liberato, N. L.

Recombinant human erythropoietin (rHuEPO) has been advocated for the treatment of anaemia in patients submitted to cancer chemotherapy. We used decision analysis to compare the cost-effectiveness of...